Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.35 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GCK | P35557 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1374041 | 0.91 | GCK (0.39) | LMNARAB9AALDH1A1POLBGCK | |
| SCHEMBL5502675 | 0.82 | LMNA (0.36) | LMNAEHMT2EHMT1APOBEC3GRAB9A | |
| SCHEMBL1679370 | 0.82 | EHMT2 (0.35) | LMNAEHMT2EHMT1APOBEC3GRAB9A | |
| SCHEMBL561821 | 0.82 | RAB9A (0.37) | LMNAEHMT2EHMT1APOBEC3GRAB9A | |
| SCHEMBL11122105 | 0.80 | EHMT2 (0.39) | EHMT2EHMT1APOBEC3GRAB9AALDH1A1 | |
| SCHEMBL8328957 | 0.78 | ALDH1A1 (0.39) | LMNARAB9AALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL28514925 | 0.78 | LMNA (0.45) | LMNAEHMT2EHMT1APOBEC3GRAB9A | |
| SCHEMBL1746858 | 0.77 | ALDH1A1 (0.35) | LMNAEHMT2EHMT1APOBEC3GRAB9A | |
| SCHEMBL4184231 | 0.76 | MEN1 (0.37) | LMNAEHMT2EHMT1APOBEC3GRAB9A | |
| SCHEMBL73690 | 0.76 | EHMT2 (0.37) | LMNAEHMT2EHMT1APOBEC3GRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149534-A1 | HAPTENIZED CORONAVIRUS SPIKE PROTEINS | BIOVAXYS LLC | 2023-05-18 | — | — | US | disclosed |
| WO-2023060220-A1 | METHODS OF IMMUNIZATION AGAINST CORONAVIRUS | BioVaxys Inc. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-4121103-A1 | HAPTENIZED CORONAVIRUS SPIKE PROTEINS | BioVaxys Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021188991-A1 | HAPTENIZED CORONAVIRUS SPIKE PROTEINS | BioVaxys Inc. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20140113371-A1 | Cryopreservation of Haptenized Tumor Cells | BERD DAVID (US) | 2014-04-24 | — | — | US | disclosed |
| US-8435784-B2 | Cryopreservation of haptenized tumor cells | THOMAS JEFFERSON UNIVERSITY | 2013-05-07 | — | — | US | disclosed |
| EP-1581242-A4 | COMPOSITIONS AND METHODS FOR MODIFYING TOXIC EFFECTS OF PROTEINACEOUS COMPOUNDS | UNIV TEXAS (US) | 2009-06-24 | — | — | EP | disclosed |
| US-20070237795-A1 | Cryopreservation of Haptenized Tumor Cells | AVAX TECHNOLOGIES, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20050233301-A1 | Cryopreservation of haptenized tumor cells | BERD DAVID | 2005-10-20 | — | — | US | disclosed |
| EP-1581242-A2 | COMPOSITIONS AND METHODS FOR MODIFYING TOXIC EFFECTS OF PROTEINACEOUS COMPOUNDS | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-1551225-A2 | CRYOPRESERVATION OF HAPTENIZED TUMOR CELLS | Avax Technologies Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004040262-A2 | COMPOSITIONS AND METHODS FOR MODIFYING TOXIC EFFECTS OF PROTEINACEOUS COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2003103389-A2 | CRYOPRESERVATION OF HAPTENIZED TUMOR CELLS | AVAX TECHNOLOGIES INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5767072-A | Therapeutic compositions comprising a CD4 peptide and methods of treatment of HIV infections | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1998-06-16 | — | — | US | disclosed |
| US-5578706-A | Methods and compositions concerning homogenous immunotoxin preparations | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 1996-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149534-A1 | HAPTENIZED CORONAVIRUS SPIKE PROTEINS | ACE2, CD14, TMPRSS2 | LMNA 4605/4885EHMT2 2542/4885EHMT1 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.